Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours

NCT06305247 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT06305247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06305247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours
Lead sponsor
Ipsen
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 3, 2024
Completion date
March 20, 2028
Enrollment
36 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, head and neck squamous cell carcinoma, melanoma, pancreatic ductal adenocarcinoma, solid tumor